
    
      This study is being done to evaluate the efficacy of levosimendan compared with placebo in
      reducing the co-primary endpoints of 30-day composite of all-cause death or use of mechanical
      assist device (IABP, LVAD or ECMO) or the composite event rate of all-cause death,
      perioperative MI, need for dialysis, or use of mechanical assist (IABP, LVAD or ECMO) in
      subjects with reduced ejection fraction undergoing cardiac surgery on CPB.
    
  